Astemizole: Difference between revisions
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
Kiran Singh (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 19: | Line 19: | ||
| routes_of_administration= Oral | | routes_of_administration= Oral | ||
}} | }} | ||
__Notoc__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | |||
==Overview== | ==Overview== | ||
| Line 53: | Line 53: | ||
<references/> | <references/> | ||
{{reflist|2}} | |||
{{antihistamines}} | {{antihistamines}} | ||
Latest revision as of 14:39, 8 April 2015
| Clinical data | |
|---|---|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Elimination half-life | 24 hours |
| Excretion | Fecal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C28H31FN4O |
| Molar mass | 458.571 |
|
WikiDoc Resources for Astemizole |
|
Articles |
|---|
|
Most recent articles on Astemizole |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Astemizole at Clinical Trials.gov Clinical Trials on Astemizole at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Astemizole
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Astemizole Discussion groups on Astemizole Patient Handouts on Astemizole Directions to Hospitals Treating Astemizole Risk calculators and risk factors for Astemizole
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Astemizole |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Astemizole (marketed under the brand name Hismanal) is a second generation antihistamine drug which has a long duration of action. Astemizole was discovered by Janssen Pharmaceutica in 1977. It has been withdrawn from the market in most countries because of rare but potentially fatal interactions with CYP3A4 enzyme inhibitors (e.g. erythromycin, grapefruit juice).
Pharmacology
Astemizole is an histamine H1-receptor antagonist. It is structurally similar to terfenadine and haloperidol (a butyrophenone antipsychotic). It has anticholinergic and antipruritic effects.
Astemizole competitively binds to histamine H1-receptor sites in the gastrointestinal tract, uterus, blood vessels, and bronchial muscle. This suppresses the formation of edema and pruritus (caused by histamine).
Astemizole does not cross the blood-brain barrier, and H1 receptor binding is mostly in the peripheral rather than central nervous system (CNS depression is thus minimal). Astemizole may also act on histamine H3 receptors, thereby producing adverse effects.
Astemizole is rapidly absorbed from the gastrointestinal tract; protein binding is around 96%.
Toxicity
Astemizole has an oral LD50 of approximately 2052mg/kg (in mice).
Research
It has been reported that this drug might prevent 97% of the muscle wasting (atrophy) that occurs in immobile, bedridden patients.[1] Testing upon mice showed that it blocked the activity of a protein present in the muscle that is involved in muscle atrophy.[2] Recent studies have also suggested anti-malarial properties of astemizole. However the concerns for the drug's longterm effects on the heart preclude its routine use in humans for this indication.
Astemizole has recently been found to be a potent treatment for malaria. It has a mechanism of action similar to chloroquine but has activity even in chloroquine-resistant parasites.[3]
External links
Footnotes
- ↑ "Drug 'could stop muscle wasting'". NetDoctor.co.uk. 25 May,2006. Retrieved 2006-05-27. Check date values in:
|date=(help) - ↑ Wang X, Hockerman GH, Green Iii HW, Babbs CF, Mohammad SI, Gerrard D, Latour MA, London B, Hannon KM, Pond AL (2006). "Merg1a K+ channel induces skeletal muscle atrophy by activating the ubiquitin proteasome pathway". FASEB J. PMID 16723379. Unknown parameter
|month=ignored (help) - ↑ Chong CR, Chen X, Shi L, Liu JO, Sullivan DJ (2006). "A clinical drug library screen identifies astemizole as an antimalarial agent". Nat Chem Biol. 2: 415&ndash, 16. doi:10.1038/nchembio806. PMID 16816845.
- Pages with script errors
- CS1 errors: dates
- Pages with citations using unsupported parameters
- CS1 maint: Multiple names: authors list
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Antihistamines
- Withdrawn drugs